AGP Executive Report
Last update: 7 hours agoPharma: Teva shares jumped 4.7% to a nearly 10-year high after US regulators approved its once-monthly schizophrenia injection Weltruza. Teva estimates peak annual sales could reach $1.5 billion to $2 billion. Banking: A court approved a class action against four major Israeli banks over whether they should pay interest on customers’ current-account balances, raising potential costs across the sector. Cost of Living: Food prices rose as much as 19.6% in four years, a Tel Aviv University study found, far faster than in the previous four-year period. Tourism: Inbound visitors remain 71% below 2019 levels, costing the economy an estimated NIS 70 million a day, according to a tourism industry analysis that also cites airport delays and cancellations.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
